The cost of a failed wet-lab program is easy to see in retrospect: reagent spend, FTE time, opportunity cost. What is harder to see in real time is how much of that cost was already determined the moment a team committed to the wrong target. The decision to investigate a particular protein is not a reversible choice; by the time you have invested in assay development, cell line validation, and the first round of experiments, you are committed in ways that have downstream consequences for six to eighteen months.
What Bad Target Selection Actually Costs
Published analyses of biotech program failures consistently identify target validity as a leading cause of late-stage attrition. When a compound fails in Phase II, the most common root cause analysis eventually traces back to whether the target was truly causal in the patient population studied. That retrospective clarity is useful for the field's learning but not useful for the team that spent three to five years and tens of millions of dollars on a program built on a flawed target hypothesis.
In earlier-stage programs, the costs are smaller but the same structural problem applies. A small biotech or academic group that spends eight months validating a target hypothesis that was avoidably wrong has not just lost those months; it has also displaced other work that could have been done with that time and those resources.
The Decision Irreversibility Problem
Target selection decisions have a peculiar property: the cost of reversing them increases rapidly over time. On day one of a program, switching to a different target costs almost nothing -- you have committed only a few days of analysis. Three months in, you have cell line models, antibody panels, and assay protocols for the original target. Switching means writing off that investment and starting the validation cycle again. Six months in, you may have preliminary in vivo data, published results, or patent applications that create organizational and external commitments that make switching genuinely difficult.
This means that the expected value of improving target selection quality is higher than it appears from just looking at the cost of individual experiments. Every dollar spent making a better initial target selection decision avoids compounding downstream costs. The leverage is large precisely because the decision is irreversible.
Hidden Costs That Rarely Get Counted
The direct reagent and FTE costs of a failed program are relatively easy to quantify. Several categories of indirect cost are harder to count but are real:
Opportunity cost of the next target. The scientists who spent a year on the wrong target could have been investigating something else. The bench capacity consumed by one program is not available to another. In resource-constrained teams, every active program directly displaces potential programs.
Credibility and morale effects. A series of target failures in early-stage work erodes internal credibility for the target selection process. This can lead to overcorrection -- increasing the evidence bar so high that programs never get started -- or to demoralization on the team that executed the failed programs conscientiously.
Investor and partner signaling. For companies with external financing or partnership relationships, a pattern of target selection failures affects how scientific leadership is perceived. The signaling cost is diffuse and delayed but real in the context of fundraising and deal-making.
Why Target Failure Often Gets Misattributed
A consistent finding in biotech post-mortems is that target validity failures are frequently attributed to other causes. A compound that fails because it hits the right target in the wrong patient population may be characterized as a patient stratification failure. A program that fails because the target was only marginally causal in the disease may be characterized as a potency or bioavailability problem. These characterizations are technically accurate -- the drug did have those properties -- but they obscure the underlying cause.
This misattribution has a practical consequence: the lessons that get learned from a failure tend to be about compound optimization rather than about the target selection process. The field invests heavily in improving medicinal chemistry and pharmacokinetics partly because failures are attributed to those causes. The actual highest-leverage intervention -- selecting better targets upstream -- receives less systematic attention because its failures are systematically misattributed.
The Case for Systematic Investment in Target Ranking
The implication is that the economic case for investing in better target ranking is stronger than a simple cost-benefit analysis of the target evaluation step would suggest. Better target selection has multiplier effects on everything that comes after it. An assay development program built on a well-validated target is more likely to generate interpretable results. An in vivo study on a high-confidence target is more likely to produce a clear signal. The downstream probability adjustments from a better-selected target propagate through the entire development path.
For early-stage teams making decisions about where to invest analytical resources, this means that spending significantly more time and resources on the target selection decision is usually justified on pure expected-value grounds, even without accounting for the indirect costs outlined above.
What Better Investment in Target Selection Looks Like
The economic argument for investing significantly in target selection quality is clear in the abstract. In practice, it requires deciding specifically where that investment goes. Additional literature review time has diminishing returns past a certain point. Experimental validation of target hypotheses in model systems has high value but high cost. Systematic multi-omics scoring of a broader candidate set before committing to a program is often the highest-leverage investment: it spends analytical resources on the decision rather than experimental resources on the wrong target.
Teams that have implemented structured target ranking report two consistent benefits beyond the immediate prioritization result. First, the structured analysis surfaces evidence conflicts and evidence gaps that were invisible in informal review, which points directly to the most important validation experiments to run. Second, maintaining the analysis in a documented, reproducible form creates a record that can be examined when programs later fail or succeed, creating feedback that gradually improves the prioritization process over time. That feedback loop is the long-run return on the investment in better target selection, and it is one of the most undervalued assets in early-stage drug discovery.